4D Molecular Therapeutics Inc (FDMT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, 4D Molecular Therapeutics Inc (FDMT) has a cash flow conversion efficiency ratio of 0.056x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($28.55 Million) by net assets ($505.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of 4D Molecular Therapeutics Inc for the company's overall valuation and market capitalisation.
4D Molecular Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how 4D Molecular Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
4D Molecular Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 4D Molecular Therapeutics Inc ranked by their cash flow conversion efficiency. Explore FDMT cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cachet Pharmaceutical Co Ltd
SHE:002462
|
0.078x |
|
Veradigm Inc.
NASDAQ:MDRX
|
0.024x |
|
Brisa Bridgestone Sabanci Lastik Sanayi ve Ticaret AS
IS:BRISA
|
0.058x |
|
Hubei Sanxia New Building Materials Co Ltd
SHG:600293
|
-0.006x |
|
Lu Thai Textile Co Ltd
SHE:000726
|
0.012x |
|
Pulike Biological Engineering
SHG:603566
|
0.034x |
|
Shaanxi Xinghua Chemistry Co Ltd
SHE:002109
|
-0.015x |
|
AGI Greenpac Limited
NSE:AGI
|
-0.035x |
Annual Cash Flow Conversion Efficiency for 4D Molecular Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of 4D Molecular Therapeutics Inc from 2017 to 2025. View current stock price of 4D Molecular Therapeutics Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $505.66 Million | $-109.08 Million | -0.216x | +18.16% |
| 2024-12-31 | $510.61 Million | $-134.59 Million | -0.264x | -7.05% |
| 2023-12-31 | $307.83 Million | $-75.79 Million | -0.246x | +34.29% |
| 2022-12-31 | $231.34 Million | $-86.69 Million | -0.375x | -72.96% |
| 2021-12-31 | $319.11 Million | $-69.13 Million | -0.217x | -9.11% |
| 2020-12-31 | $256.39 Million | $-50.91 Million | -0.199x | -139.47% |
| 2019-12-31 | $-72.97 Million | $-36.71 Million | 0.503x | -14.60% |
| 2018-12-31 | $-27.59 Million | $-16.25 Million | 0.589x | +240.11% |
| 2017-12-31 | $-19.59 Million | $8.24 Million | -0.420x | -- |
About 4D Molecular Therapeutics Inc
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production o… Read more